Pharmacological Management of Cytokine Storms

Abstract

Cytokine storm syndrome (CSS) -- a hyperinflammatory state characterised by uncontrolled immune activation, massive pro-inflammatory cytokine release (IL-6, IL-1beta, TNF-alpha, IFN-gamma, IL-18), multi-organ dysfunction, and 40-70% mortality in untreated severe cases -- occurs across aetiologically distinct contexts including severe COVID-19, CAR-T cell therapy toxicity, haemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and sepsis-associated hyperinflammation. Pharmacological intervention targets four primary nodes: corticosteroids (broad NF-kappaB suppression), JAK inhibitors (ruxolitinib, baricitinib; JAK1/2 blockade upstream of cytokine signalling), IL-6 pathway blockade (tocilizumab, sarilumab; IL-6R antagonism), and IL-1 pathway blockade (anakinra, canakinumab; IL-1R antagonism and IL-1beta neutralisation). This study evaluated 284 CSS episodes (COVID-19-associated n = 124; HLH/MAS n = 84; CAR-T toxicity n = 48; sepsis-associated n = 28; France n = 148; Estonia n = 136; 2020-2023) treated with one or more of the four pharmacological classes, developing a Cytokine Storm Management Quality Index (CSMQI) integrating treatment initiation timing, cytokine biomarker trajectory, organ dysfunction score, and drug class appropriateness to predict 28-day survival. CSMQI predicted 28-day survival with AUC = 0.883 and Pearson r = +0.84 (p < 0.001), identifying treatment initiation within 24 hours of CSS diagnosis and IL-6-directed therapy selection in COVID-19 and CAR-T contexts as the dominant determinants of survival benefit.